Table 3: The antioxidant enzyme activity and MDA of subjects (mean (SD)).

RASLET1DT1DNT2DT2DNHTNHT

SOD (U/mL)control134.57 (13.13)151.55 (14.97)142.83 (13.98)145.66 (17.97)139.63 (22.80)141.10 (21.57)149.00 (18.92)142.13 (16.30)
patients 92.85* (36.87)105.60* (33.55)131.19 (23.98)133.68* (31.36)131.69 (43.67)115.37* (38.56)131.69* (42.36)101.93* (36.34)

GPx (U/mL)control158.18 (34.41)171.20 (45.60)162.68 (42.02)159.67 (37.94)164.36 (41.25)155.39 (44.98)157.65 (39.86)159.36 (41.23)
patients 118.29* (40.30)135.85* (41.97)146.58* (39.23)127.96* (43.63)159.67 (34.76)161.33 (45.68)149.35 (48.64)135.36* (45.39)

CAT (U/mL)control1.42 (0.45)1.56 (0.37)1.54 (0.55)1.39 (0.36)1.74 (0.45)1.61 (0.47)1.52 (0.51)1.73 (0.41)
patients 1.33 (0.56)1.37 (0.53)1.39 (0.59)1.11* (0.42)1.25* (0.51)1.33* (0.51)1.47 (0.31)1.39* (0.63)

TAC (U/mL)control14.31 (5.13)15.12 (3.35)15.65 (3.63)14.96 (4.32)15.69 (3.36)16.01 (4.51)14.63 (3.39)14.78 (4.13)
patients 11.25* (4.56)13.59 (6.65)14.32 (4.13)12.15* (5.30)14.34 (4.69)14.96 (6.66)13.97 (4.63)12.01* (5.22)

MDA (nmol/mL)control3.57 (1.01)3.31 (0.94)3.14 (1.02)3.46 (1.32)3.35 (0.85)3.61 (0.98)3.44 (1.13)3.57 (1.20)
patients 4.52* (1.25)4.29* (1.37)3.08 (1.33)4.05* (1.25)3.45 (1.09)3.96 (1.23)3.55 (1.15)4.11* (0.87)

*There were significant differences between patients and control (P < 0.05).
HTN: hypertensive nephropathy; HT: heart failure.